Issue 04

REGULATION AND LEGISLATION


ACT Greens in Australia support psychedelic-assisted treatments for mental illness.


Oakland activists unveil guidelines for natural psychedelic healing ceremonies.


FDA approves esketamine-based nasal spray, Spravato, for suicidal patients.


A petition to legalise natural psychedelics in Canada reaches 13,000 signatures.


Congressman Joe Kennedy says psychedelics show promise in treating PTSD.

BUSINESS AND INVESTMENT


Medical benefits fuel the accelerating rise of the psychedelic industry.


Mydecine launches world’s first natural-sourced cGMP pharmaceutical psilocybin.


Revive develops the first set of orally dissolvable thin strips to deliver psilocybin.


Field Trip Health launches psychedelic-assisted companion app ‘Trip’.


Red Light Holland commences 3,000 sq.ft. magic truffles growth operation.


MindMed reports a strong cash position and launches European R&D subsidiary.


Tryp enters an agreement with AMRI to develop proprietary psilocybin API.


NeonMind submits an application for psilocybin research to Health Canada.

RESEARCH AND SCIENCE


Study suggests that psychedelic drugs help individuals accept distressing emotions.


Synthetic psychedelics may lead the way for pharmaceutical players.


Eleusis provides data on how psychedelics may relieve asthma symptoms.


Johns Hopkins partners with Unlimited Science for real-world psilocybin survey.

THE PSYCHEDELICS AS MEDICINE REPORT

Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.

PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.

Download your free copy now.

FEATURED ARTICLE

The psychedelics market is a nascent and fast-emerging industry, witnessing a flurry of commercial activity, including the founding of new companies, a number of IPO listings from established companies and a spate of M&A activity occurring on an almost daily basis.

Discover more about the latest innovations in our latest feature.

REACH GLOBAL INVESTORS

Exclusive sponsorship opportunities still available

PSYCH: The Psychedelics as Medicine Report Second Edition launches this month, presenting the most comprehensive analysis of the latest global developments, medical advancements as well as our exclusive market insights on this burgeoning industry.

For sponsorship information, get in touch with our global sponsorship manager, Will Sloane.

Will@prohibitionpartners.com